129 related articles for article (PubMed ID: 12804852)
1. A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230.
Fanning SL; Czesny B; Sedegah M; Carucci DJ; van Gemert GJ; Eling W; Williamson KC
Vaccine; 2003 Jul; 21(23):3228-35. PubMed ID: 12804852
[TBL] [Abstract][Full Text] [Related]
2. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity.
Bustamante PJ; Woodruff DC; Oh J; Keister DB; Muratova O; Williamson KC
Parasite Immunol; 2000 Aug; 22(8):373-80. PubMed ID: 10972844
[TBL] [Abstract][Full Text] [Related]
3. Effect of GPI anchor moiety on the immunogenicity of DNA plasmids encoding the 19-kDa C-terminal portion of Plasmodium falciparum MSP-1.
Li G; Basagoudanavar SH; Gowda DC
Parasite Immunol; 2008; 30(6-7):315-22. PubMed ID: 18422871
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid.
Vincent AA; Fanning S; Caira FC; Williamson KC
Parasite Immunol; 1999 Nov; 21(11):573-81. PubMed ID: 10583858
[TBL] [Abstract][Full Text] [Related]
5. ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.
Miura K; Deng B; Wu Y; Zhou L; Pham TP; Diouf A; Wu CK; Lee SM; Plieskatt JL; Morin MJ; Long CA
Vaccine; 2019 Apr; 37(15):2073-2078. PubMed ID: 30850239
[TBL] [Abstract][Full Text] [Related]
6. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
[TBL] [Abstract][Full Text] [Related]
7. Differences in epitope recognition, isotype and titer of antisera to Plasmodium falciparum merozoite surface protein 4 raised by different modes of DNA or protein immunization.
Wang L; Menting JG; Black CG; Stowers A; Kaslow DC; Hoffman SL; Coppel RL
Vaccine; 2000 Nov; 19(7-8):816-24. PubMed ID: 11115704
[TBL] [Abstract][Full Text] [Related]
8. Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol.
Haddad D; Liljeqvist S; Ståhl S; Hansson M; Perlmann P; Ahlborg N; Berzins K
Scand J Immunol; 1999 May; 49(5):506-14. PubMed ID: 10320644
[TBL] [Abstract][Full Text] [Related]
9. Identification of domains within Pfs230 that elicit transmission blocking antibody responses.
Tachibana M; Miura K; Takashima E; Morita M; Nagaoka H; Zhou L; Long CA; Richter King C; Torii M; Tsuboi T; Ishino T
Vaccine; 2019 Mar; 37(13):1799-1806. PubMed ID: 30824357
[TBL] [Abstract][Full Text] [Related]
10. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
[TBL] [Abstract][Full Text] [Related]
11. Pfs230: from malaria transmission-blocking vaccine candidate toward function.
Williamson KC
Parasite Immunol; 2003 Jul; 25(7):351-9. PubMed ID: 14521577
[No Abstract] [Full Text] [Related]
12. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
Teo WH; Nurul AA; Norazmi MN
Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
[TBL] [Abstract][Full Text] [Related]
13. Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum.
Belperron AA; Feltquate D; Fox BA; Horii T; Bzik DJ
Infect Immun; 1999 Oct; 67(10):5163-9. PubMed ID: 10496891
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins.
Singh K; Burkhardt M; Nakuchima S; Herrera R; Muratova O; Gittis AG; Kelnhofer E; Reiter K; Smelkinson M; Veltri D; Swihart BJ; Shimp R; Nguyen V; Zhang B; MacDonald NJ; Duffy PE; Garboczi DN; Narum DL
Commun Biol; 2020 Jul; 3(1):395. PubMed ID: 32709983
[TBL] [Abstract][Full Text] [Related]
15. In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines.
Hedstrom RC; Doolan DL; Wang R; Kumar A; Sacci JB; Gardner MJ; Aguiar JC; Charoenvit Y; Sedegah M; Tine JA; Margalith M; Hobart P; Hoffman SL
Int J Mol Med; 1998 Jul; 2(1):29-38. PubMed ID: 9854139
[TBL] [Abstract][Full Text] [Related]
16. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
17.
Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
Front Immunol; 2019; 10():1256. PubMed ID: 31231386
[TBL] [Abstract][Full Text] [Related]
18. Stage-specific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate.
Williamson KC; Fujioka H; Aikawa M; Kaslow DC
Mol Biochem Parasitol; 1996 Jun; 78(1-2):161-9. PubMed ID: 8813686
[TBL] [Abstract][Full Text] [Related]
19. Malaria DNA vaccines in Aotus monkeys.
Gramzinski RA; Maris DC; Doolan D; Charoenvit Y; Obaldia N; Rossan R; Sedegah M; Wang R; Hobart P; Margalith M; Hoffman S
Vaccine; 1997 Jun; 15(8):913-5. PubMed ID: 9234546
[TBL] [Abstract][Full Text] [Related]
20. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.
Rainczuk A; Smooker PM; Kedzierski L; Black CG; Coppel RL; Spithill TW
Vaccine; 2003 Jun; 21(21-22):3030-42. PubMed ID: 12798647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
